Article Information
History
- October 2, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Nikita Sushentsev1,*,†,
- Gregory Hamm2,†,
- Lucy Flint2,
- Daniel Birtles2,
- Aleksandr Zakirov3,
- Jack Richings2,
- Stephanie Ling2,
- Jennifer Y. Tan2,
- Mary A. McLean1,4,
- Vinay Ayyappan1,
- Ines Horvat Menih1,
- Cara Brodie4,
- Jodi L. Miller4,
- Ian G. Mills5,6,7,8,
- Vincent J. Gnanapragasam9,10,11,
- Anne Y. Warren12,
- Simon T. Barry13,
- Richard J.A. Goodwin2,††,
- Tristan Barrett1,†† and
- Ferdia A. Gallagher1,††
- 1Department of Radiology, Addenbrooke’s Hospital and University of Cambridge, Cambridge, UK
- 2Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK
- 3Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
- 4Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
- 5Patrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast, UK
- 6Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
- 7Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway
- 8Department of Clinical Science, University of Bergen, Bergen, Norway
- 9Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- 10Division of Urology, Department of Surgery, University of Cambridge, Cambridge, UK
- 11Cambridge Urology Translational Research and Clinical Trials Office, Cambridge Biomedical Campus, Addenbrooke’s Hospital, Cambridge, UK
- 12Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- 13Bioscience, Discovery, Oncology R&D, AstraZeneca, Cambridge, UK
- ↵*Corresponding author. Email: ns784{at}medschl.cam.ac.uk
↵† These authors contributed equally
Posted October 02, 2023.
